Michael S Hershfield
Overview
Explore the profile of Michael S Hershfield including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
2197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toskov V, Bali P, Hershfield M, Ehl S, Speckmann C
J Clin Immunol
. 2024 Sep;
45(1):8.
PMID: 39264481
No abstract available.
2.
Santisteban I, Arredondo-Vega F, Bali P, Dalgic B, Lee H, Kim M, et al.
J Allergy Clin Immunol
. 2024 Aug;
155(1):166-175.
PMID: 39182630
Background: Deficiency of adenosine deaminase (ADA or ADA1) has broad clinical and genetic heterogeneity. Screening techniques can identify asymptomatic infants whose phenotype and prognosis are indeterminate, and who may carry...
3.
Hicks E, Hall G, Hershfield M, Tarrant T, Bali P, Sleasman J, et al.
J Clin Immunol
. 2024 Apr;
44(5):107.
PMID: 38676811
Purpose: Patients with adenosine deaminase 1 deficient severe combined immunodeficiency (ADA-SCID) are initially treated with enzyme replacement therapy (ERT) with polyethylene glycol-modified (PEGylated) ADA while awaiting definitive treatment with hematopoietic...
4.
Lee P, Davidson B, Abraham R, Alter B, Arostegui J, Bell K, et al.
JAMA Netw Open
. 2023 May;
6(5):e2315894.
PMID: 37256629
Importance: Deficiency of adenosine deaminase 2 (DADA2) is a recessively inherited disease characterized by systemic vasculitis, early-onset stroke, bone marrow failure, and/or immunodeficiency affecting both children and adults. DADA2 is...
5.
Chen L, Mamutova A, Kozlova A, Latysheva E, Evgeny F, Latysheva T, et al.
J Allergy Clin Immunol
. 2023 May;
152(3):771-782.
PMID: 37150360
Background: Deficiency of adenosine deaminase 2 (DADA2) results in heterogeneous manifestations including systemic vasculitis and red cell aplasia. The basis of different disease phenotypes remains incompletely defined. Objective: We sought...
6.
Murguia-Favela L, Suresh S, Wright N, Alvi S, Tehseen S, Hernandez-Trujillo V, et al.
J Allergy Clin Immunol Pract
. 2023 Feb;
11(6):1725-1733.
PMID: 36736953
Background: ADAGEN, a bovine-based enzyme replacement therapy (ERT), has been used to treat adenosine deaminase severe combined immunodeficiency (ADA-SCID). In 2018, ADAGEN was replaced by REVCOVI (elapegademase), a modified bovine...
7.
Barzaghi F, Cicalese M, Zoccolillo M, Brigida I, Barcella M, Merelli I, et al.
Front Immunol
. 2022 Oct;
13:910021.
PMID: 36248833
Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive disease associated with a highly variable clinical presentation, including vasculitis, immunodeficiency, and hematologic manifestations, potentially progressing over time. The present...
8.
Cuvelier G, Logan B, Prockop S, Buckley R, Kuo C, Griffith L, et al.
Blood
. 2022 Jun;
140(7):685-705.
PMID: 35671392
Adenosine deaminase (ADA) deficiency causes ∼13% of cases of severe combined immune deficiency (SCID). Treatments include enzyme replacement therapy (ERT), hematopoietic cell transplant (HCT), and gene therapy (GT). We evaluated...
9.
Moi L, Schnider C, Riccio O, Hershfield M, Candotti F
J Clin Immunol
. 2022 Apr;
42(5):959-961.
PMID: 35449494
No abstract available.
10.
Ozer I, Kelly G, Gu R, Li X, Zakharov N, Sirohi P, et al.
Adv Sci (Weinh)
. 2022 Feb;
9(11):e2103672.
PMID: 35133079
Protein therapeutics, except for antibodies, have a short plasma half-life and poor stability in circulation. Covalent coupling of polyethylene glycol (PEG) to protein drugs addresses this limitation. However, unlike previously...